{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:28:32Z","timestamp":1786980512301,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["2019R1C1C1009875"],"award-info":[{"award-number":["2019R1C1C1009875"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10072-025-08196-6","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T22:03:29Z","timestamp":1745618609000},"page":"3919-3927","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Early prediction of refractory myasthenia gravis based on response to treatment within the first year of diagnosis"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9482-9244","authenticated-orcid":false,"given":"Hee Jo","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6750-2089","authenticated-orcid":false,"given":"Susung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4165-8901","authenticated-orcid":false,"given":"Hyung Jun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4408-8265","authenticated-orcid":false,"given":"Ha Young","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5621-0811","authenticated-orcid":false,"given":"Seung Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,26]]},"reference":[{"issue":"2","key":"8196_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","volume":"37","author":"D Grob","year":"2008","unstructured":"Grob D, Brunner N, Namba T, Pagala M (2008) Lifetime course of myasthenia Gravis. Muscle Nerve 37(2):141\u2013149. https:\/\/doi.org\/10.1002\/mus.20950","journal-title":"Muscle Nerve"},{"key":"8196_CR2","doi-asserted-by":"publisher","first-page":"175628561774913","DOI":"10.1177\/1756285617749134","volume":"11","author":"R Mantegazza","year":"2018","unstructured":"Mantegazza R, Antozzi C (2018) When myasthenia Gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord 11:1756285617749134. https:\/\/doi.org\/10.1177\/1756285617749134","journal-title":"Ther Adv Neurol Disord"},{"key":"8196_CR3","doi-asserted-by":"publisher","first-page":"175628641983224","DOI":"10.1177\/1756286419832242","volume":"12","author":"C Schneider-Gold","year":"2019","unstructured":"Schneider-Gold C, Hagenacker T, Melzer N, Ruck T (2019) Understanding the burden of refractory myasthenia Gravis. Ther Adv Neurol Disord 12:1756286419832242. https:\/\/doi.org\/10.1177\/1756286419832242","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"8196_CR4","first-page":"255","volume":"86","author":"J Suh","year":"2013","unstructured":"Suh J, Goldstein JM, Nowak RJ (2013) Clinical characteristics of refractory myasthenia Gravis patients. Yale J Biol Med 86(2):255\u2013260","journal-title":"Yale J Biol Med"},{"key":"8196_CR5","doi-asserted-by":"publisher","first-page":"Doc12","DOI":"10.3205\/000239","volume":"14","author":"SR Sudulagunta","year":"2016","unstructured":"Sudulagunta SR, Sepehrar M, Sodalagunta MB, Settikere Nataraju A, Bangalore Raja SK, Sathyanarayana D et al (2016) Refractory myasthenia gravis - clinical profile, comorbidities and response to rituximab. Ger Med Sci 14:Doc12. https:\/\/doi.org\/10.3205\/000239","journal-title":"Ger Med Sci"},{"issue":"4","key":"8196_CR6","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1007\/s00415-019-09667-5","volume":"267","author":"J Rath","year":"2020","unstructured":"Rath J, Brunner I, Tomschik M, Zulehner G, Hilger E, Krenn M et al (2020) Frequency and clinical features of treatment-refractory myasthenia Gravis. J Neurol 267(4):1004\u20131011. https:\/\/doi.org\/10.1007\/s00415-019-09667-5","journal-title":"J Neurol"},{"issue":"3","key":"8196_CR7","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/14712598.2023.2184257","volume":"23","author":"A Uzawa","year":"2023","unstructured":"Uzawa A, Utsugisawa K (2023) Biological therapies for myasthenia Gravis. Expert Opin Biol Ther 23(3):253\u2013260. https:\/\/doi.org\/10.1080\/14712598.2023.2184257","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"8196_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","volume":"15","author":"MC Dalakas","year":"2019","unstructured":"Dalakas MC (2019) Immunotherapy in myasthenia Gravis in the era of biologics. Nat Reviews Neurol 15(2):113\u2013124. https:\/\/doi.org\/10.1038\/s41582-018-0110-z","journal-title":"Nat Reviews Neurol"},{"key":"8196_CR9","doi-asserted-by":"publisher","first-page":"175628642312132","DOI":"10.1177\/17562864231213240","volume":"16","author":"H Wiendl","year":"2023","unstructured":"Wiendl H, Abicht A, Chan A, Della Marina A, Hagenacker T, Hekmat K et al (2023) Guideline for the management of myasthenic syndromes. Ther Adv Neurol Disord 16:17562864231213240. https:\/\/doi.org\/10.1177\/17562864231213240","journal-title":"Ther Adv Neurol Disord"},{"key":"8196_CR10","doi-asserted-by":"publisher","unstructured":"Alhaidar MK, Abumurad S, Soliven B, Rezania K (2022) Current treatment of myasthenia Gravis. J Clin Med 11(6). https:\/\/doi.org\/10.3390\/jcm11061597","DOI":"10.3390\/jcm11061597"},{"issue":"11","key":"8196_CR11","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","volume":"79","author":"F Piehl","year":"2022","unstructured":"Piehl F, Eriksson-Dufva A, Budzianowska A, Feresiadou A, Hansson W, Hietala MA et al (2022) Efficacy and safety of rituximab for New-Onset generalized myasthenia Gravis: the RINOMAX randomized clinical trial. JAMA Neurol 79(11):1105\u20131112. https:\/\/doi.org\/10.1001\/jamaneurol.2022.2887","journal-title":"JAMA Neurol"},{"issue":"12","key":"8196_CR12","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/s1474-4422(17)30369-1","volume":"16","author":"JF Howard Jr","year":"2017","unstructured":"Howard JF Jr., Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I et al (2017) Safety and efficacy of Eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia Gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16(12):976\u2013986. https:\/\/doi.org\/10.1016\/s1474-4422(17)30369-1","journal-title":"Lancet Neurol"},{"issue":"4","key":"8196_CR13","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1111\/ene.14675","volume":"28","author":"C Tran","year":"2021","unstructured":"Tran C, Biswas A, Mendoza M, Katzberg H, Bril V, Barnett C (2021) Performance of different criteria for refractory myasthenia Gravis. Eur J Neurol 28(4):1375\u20131384. https:\/\/doi.org\/10.1111\/ene.14675","journal-title":"Eur J Neurol"},{"issue":"5","key":"8196_CR14","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/mus.22140","volume":"44","author":"S Muppidi","year":"2011","unstructured":"Muppidi S, Wolfe GI, Conaway M, Burns TM (2011) MG-ADL: still a relevant outcome measure. Muscle Nerve 44(5):727\u2013731. https:\/\/doi.org\/10.1002\/mus.22140","journal-title":"Muscle Nerve"},{"issue":"3","key":"8196_CR15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/wnl.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A et al (2021) International consensus guidance for management of myasthenia Gravis: 2020 update. Neurology 96(3):114\u2013122. https:\/\/doi.org\/10.1212\/wnl.0000000000011124","journal-title":"Neurology"},{"issue":"3","key":"8196_CR16","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","volume":"15","author":"J Sussman","year":"2015","unstructured":"Sussman J, Farrugia ME, Maddison P, Hill M, Leite MI, Hilton-Jones D (2015) Myasthenia Gravis: association of British neurologists\u2019 management guidelines. Pract Neurol 15(3):199\u2013206. https:\/\/doi.org\/10.1136\/practneurol-2015-001126","journal-title":"Pract Neurol"},{"issue":"2","key":"8196_CR17","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/acn3.51492","volume":"9","author":"E Cort\u00e9s-Vicente","year":"2022","unstructured":"Cort\u00e9s-Vicente E, \u00c1lvarez-Velasco R, Pla-Junca F, Rojas-Garcia R, Paradas C, Sevilla T et al (2022) Drug-refractory myasthenia Gravis: clinical characteristics, treatments, and outcome. Ann Clin Transl Neurol 9(2):122\u2013131. https:\/\/doi.org\/10.1002\/acn3.51492","journal-title":"Ann Clin Transl Neurol"},{"key":"8196_CR18","doi-asserted-by":"publisher","unstructured":"Garcia-Garcia J, D\u00edaz-Maroto I, Mart\u00ednez-Mart\u00edn A, Pardal-Fern\u00e1ndez JM, Segura T (2020) A series of patients with refractory myasthenia gravis. Neurologia. https:\/\/doi.org\/10.1016\/j.nrl.2020.08.016:S0213-4853(0220)30293-30290. https:\/\/doi.org\/10.1016\/j.nrl.2020.08.016","DOI":"10.1016\/j.nrl.2020.08.016:S0213-4853(0220)30293-30290"},{"key":"8196_CR19","doi-asserted-by":"publisher","first-page":"725700","DOI":"10.3389\/fneur.2021.725700","volume":"12","author":"X Feng","year":"2021","unstructured":"Feng X, Song Z, Wu M, Liu Y, Luo S, Zhao C, Zhang W (2021) Efficacy and safety of immunotherapies in refractory myasthenia Gravis: A systematic review and Meta-Analysis. Front Neurol 12:725700. https:\/\/doi.org\/10.3389\/fneur.2021.725700","journal-title":"Front Neurol"},{"issue":"4","key":"8196_CR20","doi-asserted-by":"publisher","first-page":"231","DOI":"10.5582\/irdr.2019.01121","volume":"8","author":"N Garz\u00f3n-Orjuela","year":"2019","unstructured":"Garz\u00f3n-Orjuela N, van der Werf L, Prieto-Pinto LC, Lasalvia P, Casta\u00f1eda-Cardona C, Rosselli D (2019) Quality of life in refractory generalized myasthenia Gravis: A rapid review of the literature. Intractable Rare Dis Res 8(4):231\u2013238. https:\/\/doi.org\/10.5582\/irdr.2019.01121","journal-title":"Intractable Rare Dis Res"},{"issue":"4","key":"8196_CR21","doi-asserted-by":"publisher","first-page":"e376","DOI":"10.1212\/wnl.0000000000013121","volume":"98","author":"RJ Nowak","year":"2022","unstructured":"Nowak RJ, Coffey CS, Goldstein JM, Dimachkie MM, Benatar M, Kissel JT et al (2022) Phase 2 trial of rituximab in acetylcholine receptor Antibody-Positive generalized myasthenia Gravis: the BeatMG study. Neurology 98(4):e376\u2013e389. https:\/\/doi.org\/10.1212\/wnl.0000000000013121","journal-title":"Neurology"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08196-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-025-08196-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08196-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T05:28:05Z","timestamp":1752643685000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-025-08196-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,26]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["8196"],"URL":"https:\/\/doi.org\/10.1007\/s10072-025-08196-6","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,26]]},"assertion":[{"value":"1 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Severance Hospital Institutional Review Board (Approval No. 4-2023-1533), and was conducted in accordance with the Declaration of Helsinki. The requirement for informed consent was waived due to the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and informed consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}